论文部分内容阅读
目的对晚期妊娠合并子宫肌瘤患者在临床中的治疗情况进行分析。方法回顾性分析200例晚期妊娠合并子宫肌瘤患者的临床资料,所有患者均进行剖宫产手术,部分患者给予子宫肌瘤剔除术,并根据手术方式、子宫肌瘤类型对其进行分组,观察各组手术时间等的差异。结果术前进行诊断发现有妊娠合并子宫肌瘤108例,占全部患者的54.0%。剖宫产联合子宫肌瘤剔除术组手术时间(63.26±21.02)min、术中出血量(247.43±43.27)ml、术后恢复时间(61.43±19.77)d,单纯剖宫产组手术时间(61.43±19.77)min、术中出血量(253.26±46.83)ml、术后恢复时间(63.26±21.02)d,两组手术时间、术中出血量、术后恢复时间比较差异无统计学意义(P>0.05)。妊娠合并子宫宫颈肌瘤组手术时间为(69.43±21.36)min,明显长于妊娠合并子宫宫体肌瘤组的(59.83±17.42)min,差异具有统计学意义(P<0.05)。结论对于晚期妊娠合并子宫肌瘤的患者应综合患者子宫肌瘤的类型,大小,位置及患者的身体情况等因素做出综合判断,并对患者是否出现其他病症进行综合考虑分析。并对患者的分娩方式及术中处理方法进行有针对性的处理,使患者在治疗过程中受到的伤害降到最低。
Objective To analyze the clinical treatment of patients with advanced uterine fibroids in pregnancy. Methods A retrospective analysis of 200 cases of pregnant women with uterine fibroids clinical data, all patients were cesarean section surgery, some patients given myomectomy, and according to the surgical approach, the type of uterine fibroids were grouped to observe The operation time of each group was different. Results preoperative diagnosis found that 108 cases of uterine fibroids pregnancy, accounting for 54.0% of all patients. The operative time (63.26 ± 21.02) min, intraoperative blood loss (247.43 ± 43.27) ml, postoperative recovery time (61.43 ± 19.77) d, simple cesarean section operation time (61.43 ± 19.77) min, blood loss (253.26 ± 46.83) ml and postoperative recovery time (63.26 ± 21.02) d respectively. There was no significant difference in operative time, intraoperative blood loss and postoperative recovery time between the two groups (P> 0.05). The operation time of uterine cervix fibroids group was (69.43 ± 21.36) min in pregnancy, which was significantly longer than that in uterine fibroids group (59.83 ± 17.42) min, the difference was statistically significant (P <0.05). Conclusion Patients with advanced uterine fibroids in pregnancy should make a comprehensive judgment based on factors such as the type, size, location of the uterine fibroids and the physical condition of the patients and analyze whether patients have other diseases. And the patient’s delivery mode and intraoperative management of targeted treatment, so that patients in the course of treatment to minimize the damage suffered.